Sage Therapeutics (SAGE) Stock Forecast & Price Target

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

$13.33

+0.29 (+2.22%)

(As of 04/19/2024 ET)

Sage Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 17 Analyst Ratings

Analysts' Consensus Price Target

$39.28
194.66% Upside

High Forecast	$294.00
Average Forecast	$39.28
Low Forecast	$14.00

Type	Current Forecast 4/20/23 to 4/19/24	1 Month Ago 3/21/23 to 3/20/24	3 Months Ago 1/20/23 to 1/20/24	1 Year Ago 4/20/22 to 4/20/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)
Hold	13 Hold rating(s)	14 Hold rating(s)	15 Hold rating(s)	8 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$39.28	$41.71	$41.50	$52.23
Predicted Upside	194.66% Upside	101.88% Upside	92.17% Upside	32.97% Upside

Get Sage Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

SAGE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SAGE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sage Therapeutics Stock vs. The Competition

Type	Sage Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.12	2.68	2.49
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	199.37% Upside	986.76% Upside	12.09% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
4/18/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Outperform ➝ Sector Outperform	$34.00 ➝ $19.00	+50.44%
4/18/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform ➝ Market Perform	$25.00 ➝ $17.00	+35.24%
4/18/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
4/18/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$30.00 ➝ $16.00	+27.29%
4/17/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$24.00	+91.54%
4/17/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$28.00	+123.46%
Get the Latest News and Ratings for SAGE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
4/17/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$24.00 ➝ $14.00	+11.29%
3/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$24.00 ➝ $29.00	+55.16%
2/28/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $22.00	+0.09%
2/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $26.00	+1.96%
12/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$22.00 ➝ $20.00	-6.41%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$21.00	+4.90%
10/13/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$22.00 ➝ $25.00	+31.79%
9/7/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$19.00 ➝ $20.00	-3.10%
8/8/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$40.00 ➝ $20.00	+10.31%
8/8/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$64.00 ➝ $21.00	+25.37%
8/7/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$311.00 ➝ $294.00	+1,655.22%
5/3/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Maintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:46 PM ET.

SAGE Price Target - Frequently Asked Questions

What is Sage Therapeutics's consensus rating and price target?: According to the issued ratings of 17 analysts in the last year, the consensus rating for Sage Therapeutics stock is Hold based on the current 1 sell rating, 13 hold ratings and 3 buy ratings for SAGE. The average twelve-month price prediction for Sage Therapeutics is $39.28 with a high price target of $294.00 and a low price target of $14.00. Learn more on SAGE's analyst rating history.
Do Wall Street analysts like Sage Therapeutics more than its competitors?: Analysts like Sage Therapeutics less than other Medical companies. The consensus rating for Sage Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how SAGE compares to other companies.
Is Sage Therapeutics being downgraded by Wall Street analysts?: Over the previous 90 days, Sage Therapeutics's stock had 1 downgrade by analysts.

Does Sage Therapeutics's stock price have much upside?: According to analysts, Sage Therapeutics's stock has a predicted upside of 122.10% based on their 12-month stock forecasts.
What analysts cover Sage Therapeutics?: Sage Therapeutics has been rated by Bank of America, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Royal Bank of Canada, Scotiabank, TD Cowen, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:SAGE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sage Therapeutics (SAGE) Stock Forecast & Price Target

Sage Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

SAGE Analyst Ratings By Month

SAGE Price Targets by Month

Sage Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

SAGE Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info